RxDoctor Payments Data

Katrina Anderson, PA

Physician Assistant · Brookville, PANPI 1043779382

Payments from drug & device makers

$7,998in general payments, 2019–2025

Across 522 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$990
  • AbbVie$986
  • Amgen$794
  • AstraZeneca$620
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$599
  • Pfizer$471
  • plus $4K from 39 others

What the payments were for

  • Consulting fees$1752%
  • Food & beverage$7,82398%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,998 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$38,592
Medicare patients
198
Services billed
524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$44,895
FarxigaDapagliflozin Propanediol52$43,973
TrulicityDulaglutide41$36,964
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$19,779
OzempicSemaglutide19$18,916
JardianceEmpagliflozin14$18,356
MyrbetriqMirabegron24$18,250
Repatha SyringeEvolocumab23$11,955
Spiriva RespimatTiotropium Bromide13$6,464
Repatha SureclickEvolocumab13$5,970
Incruse ElliptaUmeclidinium Bromide11$3,448
Levothyroxine Sodium154$1,131
Gabapentin62$1,109
Metoprolol Succinate57$962
Atorvastatin Calcium104$881

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$471$44,89554 claims
AstraZenecaFarxiga$620$43,97352 claims
Lilly USA, LLCTrulicity$412$36,96441 claims
Boehringer IngelheimJardiance, Spiriva Respimat$327$24,82127 claims
GSKTrelegy Ellipta, Incruse Ellipta$180$23,22733 claims
Novo NordiskOzempic$990$18,91619 claims
Astellas Pharma US IncMyrbetriq$152$18,25024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Brookville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →